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Abstract
Rationale Acute administration of clozapine (a gold standard
of atypical antipsychotics) disrupts avoidance response in
rodents, while repeated administration often causes a tolerance
effect.
Objective The present study investigated the neuroanatomical
basis and receptor mechanisms of acute and repeated effects of
clozapine treatment in the conditioned avoidance response test
in male Sprague-Dawley rats.
Methods 2,5-dimethoxy-4-iodo-amphetamine (DOI, a prefer-
ential 5-HT2A/2C agonist) or quinpirole (a preferential dopa-
mine D2/3 agonist) was microinjected into the medial prefron-
tal cortex (mPFC) or nucleus accumbens shell (NAs), and
their effects on the acute and long-term avoidance disruptive
effect of clozapine were tested.
Results Intra-mPFC microinjection of quinpirole enhanced
the acute avoidance disruptive effect of clozapine
(10 mg/kg, sc), while DOI microinjections reduced it
marginally. Repeated administration of clozapine
(10 mg/kg, sc) daily for 5 days caused a progressive
decrease in its inhibition of avoidance responding,
indicating tolerance development. Intra-mPFC microinjec-
tion of DOI at 25.0 (but not 5.0)μg/side during this period
completely abolished the expression of clozapine toler-
ance. This was indicated by the finding that clozapine-
treated rats centrally infused with 25.0 μg/side DOI did
not show higher levels of avoidance responses than the
vehicle-treated rats in the clozapine challenge test.
Microinjection of DOI into the mPFC immediately before
the challenge test also decreased the expression of cloza-
pine tolerance.
Conclusions Acute behavioral effect of clozapine can be en-
hanced by activation of the D2/3 receptors in the mPFC.
Clozapine tolerance expression relies on the neuroplasticity
initiated by its antagonist action against 5-HT2A/2C receptors
in the mPFC.
Keywords 5-HT2A/2C receptor . D2/3 receptor . Medial
prefrontal cortex . Clozapine . Conditioned avoidance
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Introduction
As a prototypical atypical antipsychotic drug, clozapine pos-
sesses a superior efficacy in the treatment of schizophrenia,
especially for refractory patients who respond poorly to other
antipsychotic medications and patients with a high suicide risk
(Kane et al. 1988; McEvoy et al. 2006). The neurobiological
mechanisms responsible for its superiority are not known. At
the receptor level, clozapine’s mechanism of action is thought
to include more potent blockade of serotonin 5-HT2A than of
dopamine D2 receptor (Meltzer 2002). However, this property
does not distinguish it from other atypical antipsychotic drugs,
nor could it be used to explain its therapeutic effects. This is
because the unique clinical therapeutic effects of clozapine
manifest only after some period of repeated drug treatment,
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which inevitably induces long-term plastic changes in the
brain beyond its acute receptor binding actions. In addition,
recent evidence does suggest that the receptor mechanisms
underlying the acute effect of clozapine are distinct from that
of its chronic effect (Li et al. 2010, 2012). Neuroanatomically,
clozapine also does not seem to possess a higher regional
specificity than other drugs (Borison and Diamond 1983;
Kuroki et al. 1999). Furthermore, the exact neural network
upon which clozapine exerts its therapeutic effects has not
been elucidated, although the medial prefrontal cortex
(mPFC) has been implicated as an important brain region
(Ohashi et al. 2000; Pehek and Yamamoto 1994). Overall, it
seems difficult to distinguish clozapine from other antipsy-
chotic drugs based on current understandings of its neurobio-
logical mechanisms of action.
Remarkably, at the behavioral level, clozapine can be
singled out on the basis of its effect in the conditioned
avoidance response (CAR) and phencyclidine (PCP)-in-
duced hyperlocomotion tests, two widely used and validat-
ed behavioral measures of antipsychotic activity (Li et al.
2007; Sanger 1985; Wadenberg and Hicks 1999; Zhao
et al. 2012). Repeated and intermittent exposures to most
antipsychotic drugs (e.g., haloperidol, olanzapine,
aripiprazole, risperidone, or asenapine) often lead to a
progressive and persistent increase in their ability to sup-
p r e s s a v o i d a n c e r e s p o n s e a n d PCP - i n d u c e d
hyperlocomotion, known as antipsychotic sensitization.
However, clozapine is the only drug that causes a decrease
in its ability to do so (termed clozapine tolerance) (Feng
et al. 2013; Li et al. 2007; Li et al. 2010, 2012; Qiao et al.
2013; Qin et al. 2013; Zhang and Li 2012). Clozapine
tolerance thus represents an interesting form of
neuroplasticity. It might be one characteristic effect that
distinguishes this drug from other antipsychotic drugs,
although its clinical implications are still not clear. We
hypothesized that clozapine tolerance may be a unique
feature linked to its superior therapeutic efficacy and may
reflect its procognitive effect. Therefore, if we could un-
derstand the neuroanatomical basis and receptor mecha-
nisms of clozapine tolerance in these preclinical behavioral
tests, we may be able to delineate the neurobiological
mechanisms responsible for clozapine’s unique therapeutic
effect. In the present study, we addressed this issue using a
combination of microinjection and pharmacological tech-
niques in the CAR test. We first determined that the mPFC
is one critical brain region where clozapine acts to achieve
its acute disruptive effect of avoidance, likely through its
actions on D2/3 and 5-HT2A/2C receptors (to a lesser ex-
tent). Next, we showed that the expression of clozapine
tolerance, but not the tolerance induction is dependent on
5-HT2A/2C receptors in the mPFC. This study illustrates an
interesting dissociated receptor mechanism underlying the
acute effect of clozapine and its repeated effect.
Materials and methods
Animals
Male Sprague-Dawley rats (226–250 g upon arrival, Charles
River, Portage, MI) were housed in pairs in transparent poly-
carbonate cages (48.3 cm×26.7 cm×20.3 cm) and maintained
on a 12:12 light/dark schedule. Food and water were provided
ad libitum. Room temperature was maintained at 22±1 °C
with a relative humidity of 45–60 %. All procedures were
approved by the IACUC at the University of Nebraska-
Lincoln. All behavioral tests were conducted in the light cycle
between 9:00 and 17:00.
Conditioned avoidance response training procedure
After 5 days of acclimation to the animal facility, rats were
first handled and habituated to the custom-built two-compart-
ment shuttle boxes (Med Associates, VT, USA) for 2 days
(20 min/day). Over the next 2 weeks, they were trained to
acquire avoidance responding in 10 sessions (1 session/day)
(Feng et al. 2013; Li et al. 2010). Each training session
consisted of 30 trials and each trial started with a presentation
of a conditioned stimulus (CS, 76 dBwhite noise) for 10 s. If a
subject moved from one compartment into the other during
the CS presentation, the CS was terminated and an avoidance
response was recorded. If the rat did not move across the
chambers during the CS, a footshock (unconditioned stimulus,
US, 0.8 mA)was immediately delivered to the metal grid floor
for a maximum of 5 s. A shuttling response during this period
was recorded as an escape. If the rat did not respond during the
entire 5 s presentation of the shock, the trial was terminated
and the next trial started after an intertrial interval of 30–60 s.
Only those rats (119 out of 156) that reached the training
criterion (minimum 70 % avoidance response in each of the
last two sessions) were used in the subsequent drug tests.
Surgery
One day after the CAR training, rats were anesthetized using a
mixture of ketamine HCl (90 mg/kg) and xylazine (4 mg/kg)
(ip), and implanted with bilateral stainless-steel guide cannu-
las (22 gauge; Plastics One) into the NAs or the mPFC. To
avoid the lateral ventricles and to allow a slanted cannula
angle aimed at the NAs, the incisor bar was set at 5.0 mm
above interaural zero and the coordinates were:
anteroposterior (AP) +3.4 mm, mediolateral (ML) ±1.0 mm,
dorsoventral (DV) −5.7 mm (Reynolds and Berridge 2001;
Richard and Berridge 2011). For mPFC cannulation, the inci-
sor bar was set at −3.4 mm and the coordinates were: AP +
3.0 mm, ML ±0.75 mm, DV −2.2 mm (Paxinos and Watson
2004). All rats were allowed 6–8 days of recovery time before
being used in the subsequent drug tests.
1220 Psychopharmacology (2015) 232:1219–1230
Drugs and microinjections
Clozapine (CLZ, a gift from the NIMH drug supply
program) was dissolved in 1.0 % glacial acetic acid in
sterile distilled water and administrated subcutaneously at
10.0 mg/kg in all experiments. This dose of CLZ pro-
duces a reliable disruption on avoidance responding and
is commonly used in the comparative study of antipsy-
chotic drugs (Feng et al. 2013; Li et al. 2010, 2011,
2012; Mead and Li 2009; Qiao et al. 2013; Sun et al.
2009; Zhang and Li 2012; Zhao et al. 2012). It also gives
rise to clinically relevant striatal dopamine D2 occupan-
cies in rats (40–60 %) (Kapur et al. 2003; Wadenberg
et al. 2001b). Quinpirole (QUI) and 2,5-dimethoxy-4-
iodo-amphetamine (DOI) (RBI-Sigma, Natick, MA) were
dissolved in 0.9 % saline (SAL) and were microinjected
through 10-μl Hamilton syringes mounted on infusion
pumps (Fisher Scientific) via polyethylene tubing (PE
10) attached to a 28-gauge injector (Plastics One), which
extended 2.0 or 1.5 mm below the tips of the guide
cannulas in the NAs or mPFC, respectively. We tested
QUI at 0.0, 1.0, 5.0, and 10.0 μg/0.5 μl/side, and DOI at
0.0, 1.0, 5.0, and 25.0 μg/0.5 μl/side, based on previous
work showing that these doses are effective at producing
behavioral alterations in rats, including prepulse inhibi-
tion, impulsive behavior, psychomotor response to co-
caine (Beyer and Steketee 2000; Sipes and Geyer 1997;
Sotoyama et al. 2011; Wan and Swerdlow 1993;
Wischhof et al. 2011). The bilateral microinjection
(0.5 μl at 0.5 μl/min) started 1 min after injector inser-
tions, and the injectors remained in place for an addition-
al 1 min post infusion to allow for drug diffusion.
Experiment 1: Effects of intra-NAs or intra-mPFC infusions
of QUI or DOI on acute CLZ-induced avoidance disruption
In this experiment, we intended to determine the possible
brain sites where CLZ acts to disrupt avoidance responding
by centrally infusing a preferential dopamine D2/3 receptor
agonist (QUI) or serotonin 5-HT2A/2C receptor agonist (DOI)
into the NAs or mPFC, two possible sites implicated in the
action of CLZ (Atkins et al. 1999; Robertson et al. 1994;
Young et al. 1999). After the CAR training, 46 rats were
implanted with sterile guide cannulas bilaterally into the
NAs or mPFC. After recovery, they were first given a predrug
retraining session to ensure a high level of avoidance
responding (>70 % avoidance response) before drug testing.
Four groups of rats were tested: NAs-QUI (n=12), NAs-DOI
(n=12), mPFC-QUI (n=11), and mPFC-DOI (n=11). On the
first drug test day, rats were injected with CLZ 10 mg/kg.
Thirty minutes later, they were centrally infused with one of
four doses of QUI (0.0, 1.0, 5.0, and 10.0 μg/0.5 μl/side) or
DOI (0.0, 1.0, 5.0, and 25.0 μg/0.5 μl/side). Rats were then
placed in the CAR boxes and tested for avoidance (20 trials) at
45 and 95 min after the CLZ injection in an attempt to capture
the time course of acute action of CLZ. Rats were returned to
their home cages during the test interval. Rats remained in
their home cages for the following day. On the third day, rats
were given a retraining session (30 trials) to return their
avoidance response to the predrug levels. One day later, the
second round of drug testing under a different dose of QUI or
DOI was initiated. This 3-day cycle (day 1: drug test, day 2:
rest, day 3: retraining) was repeated four times until all four
doses of QUI or DOI had been tested based on a Latin-square
design, which provided a random sequence of administered
doses in rats.
Experiment 2: Effects of intra-mPFC infusions of DOI
during the induction phase on CLZ tolerance
Results from Experiment 1 indicated that the mPFC is one
likely brain site where CLZ acts to disrupt avoidance
responding. Given the preferential antagonist action of CLZ
on 5-HT2A/2C over D2/3, and the finding that D2/3 activation by
QUI potentiates rather than diminishes the acute and repeated
effects of CLZ (Li et al. 2010), we hypothesized that 5-HT2A/
2C receptor activation in the mPFC would decrease CLZ
tolerance. In Experiment 2, we tested this hypothesis using a
between-subjects design. After the CAR training, 48 rats were
implanted with sterile guide cannulas bilaterally into the
mPFC. After recovery, they were first given a predrug
retraining session to ensure a high level of avoidance
responding (>70 % avoidance response) before drug testing.
Then, they were allocated to the following six groups
(n=8/group) based on a complete factorial design [2 sys-
temic injection (vehicle (VEH) and CLZ)×3 central injec-
tion (VEH, DOI 5, and DOI 25)]: VEH-SAL, VEH-DOI 5,
VEH-DOI 25 and CLZ-SAL, CLZ-DOI 5, CLZ-DOI 25.
All rats were first tested under CLZ or vehicle every other
day for five sessions (30 CS-US trials/session). At the
beginning of each test session, rats were first injected with
CLZ (10 mg/kg, sc) or sterile water with 1.0 % glacial
acetic acid (VEH), then centrally infused with SAL, DOI 5,
or DOI 25 μg/0.5 μl/side into the mPFC 30 min later. Ten
minutes later, they were placed in the avoidance boxes and
tested for 30 trials. One day after the 5th CLZ test, all rats
were retrained drug-free under the CS-only condition for 1
session and under the CS-US condition for another session
the following day to bring their avoidance back to the
predrug level before the final challenge test to assess the
expression of CLZ tolerance (Feng et al. 2013; Li et al.
2010, 2012). On the challenge test, all rats were injected
with CLZ 10 mg/kg (sc) and tested for avoidance perfor-
mance in the CS-only condition (30 trials) 1 h later. No
central injection was conducted.
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Experiment 3: Effects of intra-mPFC infusions of DOI
during the expression phase on CLZ tolerance
Experiment 2 showed that intra-mPFC infusion of DOI
(25 μg/0.5 μl/side) during the tolerance induction phase
completely abolished the expression of CLZ tolerance.
Experiment 3 examined how activation of prefrontal 5-
HT2A/2C receptor by DOI immediately prior to the challenge
test would affect the expression of CLZ tolerance. After the
CAR training, 25 rats that reached the training criterion were
implanted with sterile guide cannulas bilaterally into the
mPFC. After recovery, they were first given a predrug
retraining session to ensure a high level of avoidance
responding (>70 % avoidance response) before drug testing.
Then, they were matched and assigned into three groups (n=
8-9/group): VEH-SAL, CLZ-SAL, and CLZ-DOI 25. They
were first repeatedly tested for avoidance response under CLZ
(10 mg/kg, sc, −45 min) or vehicle every other day for five
sessions (30 CS-US trials/session). After 2 days of retraining
following the last test session, all rats were challenged with
CLZ (10 mg/kg, sc) and tested for avoidance response in the
CS-only condition (30 trials) 1 h later. Fifteen minutes before
the challenge test, rats in the CLZ-DOI 25 group were cen-
trally infused with DOI 25 μg/0.5 μl/side into the mPFC,
whereas rats in the other groups (the VEH-SAL and CLZ-
SAL) were infused with saline.
Histology
At the end of behavioral tests, rats were sacrificed and per-
fused (Gao et al. 2013). Their brains were extracted and the
injection sites were verified as previously reported (Gao et al.
2013). The location of the injection site was mapped onto a
stereotaxic atlas (Paxinos and Watson 2004) (Fig. 1).
Statistical analysis
The avoidance data were expressed as the mean percent (i.e.,
number of avoidances/total number of trials)+SEM. Data
from Experiment 1 were analyzed using two-way repeated-
measures analysis of variance (ANOVA) followed by post hoc
LSD pairwise tests and/or one-way repeated-measures
ANOVAwhen needed. The two within-subjects factors were
“test time” (three levels: predrug day, 45 min, and 95 min on
the drug day) and “treatment” (QUI, or DOI). In Experiments
2 and 3, avoidance data from the five drug tests were analyzed
with repeated-measures ANOVA followed by post hoc
Tukey’s test. The between-subjects factor were “CLZ” and
“DOI” treatment (Experiment 2), or “DOI” treatment
(Experiment 3), while within-subjects factor was “test day”.
Data from the challenge tests were analyzed with two-way
ANOVAwith the between-subjects factors being “CLZ” and
“DOI” treatment (Experiment 2), or one-way ANOVA
(Experiment 3), followed by post hoc Tukey’s tests.
Avoidance data on the predrug day in Experiments 2 and 3
were analyzed using one-way ANOVA. For all comparisons,
significant difference was assumed at p<0.05, and all data
were analyzed using SPSS version 21. Thirteen rats from all
three experiments showed either sickness, or cannula failure,
or misplacement, and they were excluded from data analysis.
The final number of rats in different groups is indicated in the
figure legends.
Results
Experiment 1: Effects of intra-NAs or intra-mPFC infusions
of QUI or DOI on acute CLZ-induced avoidance disruption
Figure 2a, b shows the mean percentage of avoidance re-
sponse on the predrug and CLZ test days from rats that
received central infusions of QUI or DOI into the NAs. For
QUI (Fig. 2a), two-way repeated-measures ANOVA showed a
main effect of test time (F(2, 16)=76.549, p<0.001), but no
main effect of QUI (F(3, 24)=0.992, p=0.445), nor their
interaction (F(6, 48)=0.600, p=0.729). Post hoc pairwise tests
for test time confirmed that acute CLZ treatment significantly
suppressed avoidance response at 45 and 95 min on the drug
test days (both ps<0.001), compared to the predrug day.
However, intra-NAs infusion of QUI at all three doses (1, 5,
10 μg/0.5 μl/side) had no effect on the avoidance suppressive
effect of CLZ. For DOI (Fig. 2b), the same analysis showed a
main effect of test time (F(2, 14)=185.846, p<0.001), but no
main effect of DOI (F(3, 21)=0.992, p=0.445), nor their
interaction (F(6, 42)=1.224, p=0.313). Post hoc pairwise tests
for test time confirmed that acute CLZ treatment significantly
suppressed avoidance response at 45 and 95 min on the drug
test days (both ps<0.001), compared to the predrug day.
Again, intra-NAs infusion of DOI at all three doses (1, 5,
25 μg/0.5 μl/side) did not alter the avoidance suppressive
effect of CLZ.
Figure 2c, d shows the mean percentage of avoidance re-
sponse on the predrug and drug test days from rats that received
central infusions of QUI or DOI into the mPFC. For QUI
(Fig. 2c), two-way repeated-measures ANOVA showed a main
effect of test time (F(2, 20)=256.925, p<0.001) and a main
treatment effect of QUI (F(3, 30)=3.058, p=0.043), but no
interaction between the two (F(6, 60)=2.216, p=0.054). Post
hoc pairwise tests for test time confirmed that acute CLZ treat-
ment significantly suppressed avoidance response at 45 and
95 min on the drug test days (both ps<0.001), compared to
the predrug day. Intra-mPFC infusion of QUI dose-dependently
potentiated the avoidance suppressive effect of CLZ, as post hoc
pairwise tests for treatment revealed that CLZ-treated rats cen-
trally infused with QUI at 10 μg/0.5 μl/side (p=0.030), but not
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at 1 and 5 μg/0.5 μl/side (both ps>0.137) had significantly
fewer avoidance responses than the vehicle controls. For DOI
(Fig. 2d), two-way repeated-measures ANOVA showed a main
effect of test time (F(2, 16)=81.247, p<0.001) and the main
Fig. 1 Histological
representations of infusion sites
and schematic diagrams showing
the location of the injector tips in
the nucleus accumbens shell
(Experiment 1) and medial
prefrontal cortex (Experiments 1,
2, and 3). Data are reconstructed
from Paxinos and Watson (2004).
Numbers to the left of the sections
indicate anteroposterior distance
from bregma in millimeters. The
arrow denotes the infusion
placement
Fig. 2 Effects of microinjection
of quinpirole (QUI) at 0, 1, 5, or
10 μg/side or DOI at 0, 1, 5, or
25 μg/side into the nucleus ac-
cumbens shell (NAs; a, b) or me-
dial prefrontal cortex (mPFC; c,
d) on the acute CLZ (10.0 mg/kg,
sc)-induced avoidance disruption.
n=9, 8 for NAs—QUI or DOI,
and n=11, 9 for mPFC—QUI or
DOI, respectively. Each data
point represents the percentage
avoidance response (Mean+
SEM, number of avoidance re-
sponses divided by the total
number of trials) made by rats
during the predrug and the drug
test days . Rats received a central
infusion 30 min after systematic
CLZ injection (10.0 mg/kg, sc),
and were tested at 45 and 95 min
after CLZ injection (10 and
60 min after the central infusion).
*p<0.05 in comparison to the
VEH group during each test
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effect of DOI (F(3, 24)=3.156, p=0.043), and an interaction
between the two (F(6, 48)=2.340, p=0.046). Post hoc pairwise
tests for test time confirmed that acute CLZ treatment signifi-
cantly suppressed avoidance response at 45 and 95 min on the
drug test days (both ps<0.001), compared to the predrug day.
The main DOI effect was due to the differences between DOI 5
and DOI 1 (p=0.033) and between DOI 5 and DOI 25
(p=0.010). Because of the significant interaction between DOI
and test time, one-way ANOVAwas used to analyze the group
differences at each test time point. There was no significant
group difference on the predrug day (F(3, 24)=1.926,
p=0.152). However, there was a marginal significant effect of
DOI dose at 45 min (F(3, 24)=2.760, p=0.064) and 95 min
(F(3, 24)=2.904, p=0.056). These findings suggest that acute
effect of CLZ can be potentiated by activation of D2/3 receptors
in the mPFC.
QUI and DOI microinjected into the NAs or mPFC did not
affect the CLZ’s suppression of intertrial crossing (Fig. 3), nor
escape responding (see Fig. SI for details). Two-way repeated-
measures ANOVA followed by post hoc tests revealed that the
number of intertrial crossing decreased significantly at 45 and
95 min (all p<0.001) on the drug days than the predrug day,
but infusion of QUI or DOI into NAs or mPFC had no effect.
The number of escape responses increased significantly at 45
and 95 min on the drug day than the predrug day (all
p<0.001). These data suggest that the D2/3 receptors and 5-
HT2A/2C in the mPFC had no effect on CLZ’s effect on the
intertrial crossing and escape responses in this experimental
setup.
Experiment 2: Effects of intra-mPFC infusions of DOI
during the induction phase on CLZ tolerance
Figure 4a shows the mean percentage of avoidance response
on the predrug day and throughout the five drug test days. All
groups had a high level of avoidance responding on the
predrug day (one-way ANOVA: F(5, 38)=0.142, p=0.981).
Throughout the five drug test days, systemic CLZ treatment
significantly decreased avoidance response, but this avoid-
ance suppressive effect was gradually attenuated over time, a
clear sign of CLZ tolerance development. Intra-mPFC DOI
infusion did not affect the acute effect of CLZ nor the toler-
ance development. Repeated-measures ANOVA (i.e., “CLZ
and DOI treatments” as two between-subject factors and “test
day” as a repeated within-subjects factor) revealed a main
effect of CLZ treatment (F(1, 38)=184.674, p<0.001), test
day (F(4, 152)=18.538, p<0.001), and a significant interac-
tion between the two (F(4, 152)=10.868, p<0.001), but there
was no main effect of DOI (F(2, 38)=1.058, p=0.357), no
DOI×CLZ interaction (F(2, 38)=0.735, p=0.486), nor test
day×DOI×CLZ interaction (F(2, 38)=2.931, p=0.065). CLZ
treatment also decreased the intertrial crossing through the
five drug test days. Repeated-measures ANOVA revealed a
main effect of CLZ treatment (F(1, 38)=79.63, p<0.001),
Fig. 3 Number of intertrial
crossings made by rats on the
predrug and five drug test days.
On each drug test day, rats
received a central infusion of
quinpirole (QUI) at 0, 1, 5, or
10 μg/side or DOI at 0, 1, 5, or
25 μg/side into the nucleus ac-
cumbens shell (NAs; a, b) or me-
dial prefrontal cortex (mPFC; c,
d) 30 min after systematic CLZ
injection (10.0 mg/kg, sc), and
were tested at 45 and 95 min after
CLZ injection (10 and 60 min af-
ter the central infusion)
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DOI (F(2, 38)=5.102, p=0.011), test day (F(4, 152)=4.209,
p=0.003), and a significant interaction of CLZ×DOI (F(2,
38)=10.473, p<0.001) (Fig. 4b). Inspection of Fig. 4b reveals
that DOI at 25μg suppressed the intertrial crossing in a similar
manner as did CLZ, suggesting that either activation or sup-
pression of cortical 5-HT2A/2C receptors could decrease motor
or motivational suppressing effects of CLZ.
Figure 4c shows the mean percentage of avoidance re-
sponse on the predrug day (F(5, 38)=1.006, p=0.428) and
on the CLZ challenge day. Two-way ANOVA of the avoid-
ance performance on the challenge day revealed a signifi-
cant effect of CLZ treatment (F(1, 38)=31.796, p<0.001),
DOI treatment (F(2, 38)=6.412, p=0.004), and a signifi-
cant interaction between the two (F(2, 38) = 4.295,
p=0.021). Subsequent one-way ANOVA followed by post
hoc Tukey’s tests revealed that the CLZ-SAL group and
CLZ-DOI 5 group made significantly more avoidance re-
sponses than the corresponding VEH groups (both
ps<0.001), confirming the CLZ tolerance effect. More im-
portantly, this tolerance effect was absent in the CLZ-DOI
25 group, as it did not differ significantly from the VEH-
DOI 25 (p=0.366), suggesting that intra-mPFC infusion of
DOI at 25.0 μg/0.5 μl/side during the induction period of
CLZ tolerance completely abolished CLZ tolerance, de-
spite the fact that DOI at this dose had no effect on the
day-to-day avoidance disruptive effect of CLZ.
On the intertrial crossing, two-way ANOVA revealed a
main effect of CLZ treatment (F(1, 38)=42.013, p<0.001),
DOI treatment (F(2, 38)=11.451, p<0.001), and a significant
interaction between the two (F(2, 38)=7.552, p=0.002) on the
CLZ challenge day. Subsequent one-way ANOVA followed
by post hoc tests revealed that the CLZ-SAL group (p=0.004)
and CLZ-DOI 5 group (p=0.001), but not the CLZ-DOI 25
group (p=0.951) made significantly more crossings than the
corresponding VEH groups, indicating a tolerance effect of
CLZ on intertrial crossing which was abolished by DOI (at
25 μg/0.5 μl/side) (Fig. 4d). Throughout the 5 days of drug
treatment, CLZ-treated groups had higher levels of escapes.
However, with repeated treatment and the increase of avoid-
ance responses, it was gradually reduced. Intra-mPFC infu-
sion of DOI at all three doses had no effect on this behavior
(see Fig. SII for details).
Experiment 3: Effects of intra-mPFC infusions of DOI
during the expression phase on CLZ tolerance
Figure 5a shows the mean percentage of avoidance response
on the predrug day and during the five drug test days. We
replicated the acute avoidance disruptive effect of CLZ and
the developmental process of CLZ tolerance, as confirmed by
the repeated-measures ANOVA showing a main effect of CLZ
treatment (F(2, 21)=9.091, p=0.001), test day (F(4, 84)=
Fig. 4 Effects of microinjection
of DOI into the medial prefrontal
cortex during the induction phase
of CLZ tolerance. The data
represent the percentage
avoidance response and number
of intertrial crossings (Mean+
SEM) made by rats during the
predrug and five drug test days (a,
b), and on the retraining day and
the challenge test day (c, d). Rats
received either systemic vehicle
or CLZ (10.0 mg/kg, sc)
treatment in combination with
central DOI treatment (0, 5 or
25 μg/side; n=6, 8, 8 for VEH;
n=7, 8, 7 for CLZ) for five test
days and were challenged with
CLZ (10.0 mg/kg) after two drug-
free retraining days. ***p<0.001,
**p<0.01 in comparison to the
corresponding group (c, d)
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15.438, p<0.001), and a significant interaction between the
two (F(8, 84)=4.293, p<0.001). Correspondingly, the escape
responses were higher in the CLZ-treated groups and gradu-
ally decreased with the increase of avoidance responses (see
Fig. SIII for details).
Figure 5c shows the mean percentage of avoidance re-
sponse on the predrug day (F(2, 21)=0.703, p=0.507) and
the CLZ challenge day (F(2, 21)=9.556, p=0.001). The
CLZ-SAL group had significantly higher avoidance than
the VEH-SAL group (p=0.001), confirming the CLZ toler-
ance effect. More interestingly, the CLZ-DOI 25 group did
not differ from the VEH-SAL group (p=0.344), but had
significantly lower avoidance than the CLZ-SAL group
(p=0.024), suggesting the intra-mPFC infusion of DOI at
25.0 μg/0.5 μl/side prior to the challenge test blocked the
expression of CLZ tolerance.
CLZ treatment decreased the number of intertrial crossings
through the five drug test days (Fig. 5b). Repeated-measures
ANOVA revealed a main effect of CLZ treatment (F(2, 21)=
48.273; p<0.001), test day (F(4, 84)=6.077; p<0.001), but no
significant interaction between the two (F(8, 84)=1.402;
p=0.208). Post hoc Tukey’s test confirmed that the VEH-
SAL group made significant more crossings than the CLZ-
DOI 25 and CLZ-SAL (both ps<0.001). On the CLZ chal-
lenge day, the CLZ effect was still significant (F(2, 21)=
5.871, p=0.009), with the CLZ-SAL group making more
crossings than the VEH-SAL group (p=0.007), confirming
the CLZ tolerance effect on intertrial crossing. Interestingly,
DOI did not significantly block this tolerance (p=0.328)
(Fig. 5d).
Discussion
Using a pharmacological and microinjection approach, we first
demonstrated that the acute avoidance disruptive effect of CLZ
could be enhanced by activating the D2/3 receptors in the
mPFC and reduced to some extent by activating the prefrontal
5-HT2A/2C receptors. A more important finding is that the
expression of CLZ tolerance relies on the neuroplasticity initi-
ated by its antagonist action against 5-HT2A/2C receptors in the
mPFC. Specifically, in Experiment 1, we showed that intra-
mPFC infusion of QUI dose-dependently potentiated the
avoidance suppressive effect of CLZ, as CLZ-treated rats
centrally infused with QUI at 10 μg/0.5 μl/side but not at 1
and 5 μg/0.5 μl/side into the mPFC made significantly fewer
avoidance responses than the CLZ-treated ones but centrally
infused with vehicle. Intra-mPFC infusion of DOI appeared to
have an opposite effect as did QUI. It marginally reduced the
avoidance suppressive effect of CLZ in this within-subjects
design. Both drugs infused into the NAs did not affect this
effect of CLZ, thus, whether the NAs is involved in the
behavioral effects of CLZ is equivocal and need to be further
Fig. 5 Effects of microinjection
of DOI into the medial prefrontal
cortex on the challenge day on the
expression of clozapine tolerance.
The data represent the percentage
avoidance response and number
of intertrial crossings (Mean+
SEM) made by rats during the
predrug and five drug test days (a,
b), and on the retraining day and
the challenge test day (c, d),
respectively. Rats received
systemic vehicle or CLZ
(10.0 mg/kg, sc) injection for five
test days and were challenged
with CLZ (10.0 mg/kg) after two
drug-free retraining days. On the
challenge test day, rats received a
central infusion of saline (VEH-
SAL and CLZ-SAL, n=8/group)
or DOI 25 μg/side (CLZ-DOI 25,
n=8) 15 min before the test.
**p<0.01, *p<0.05 in
comparison to the corresponding
group (c, d)
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investigated. Regarding the effects of repeated CLZ adminis-
trations, we showed that microinjection of DOI (a preferential
5-HT2A/2C agonist) into the mPFC completely abolished the
tolerance expression when it was infused during the induction
phase (Experiment 2), and reduced it when it was infused right
before the challenge test (Experiment 3). The same central
treatment did not affect the acute avoidance suppressive
effect of CLZ and the tolerance development. These find-
ings imply that the receptor mechanisms (e.g., primarily
D2/3 and 5-HT2A/2C receptors in the mPFC) that regulate the
acute effect of CLZ are likely different from those (primar-
ily 5-HT2A/2C receptors in the mPFC) that modulate CLZ
tolerance.
Our previous studies suggest that 5-HT2A receptors appear
to be critical for CLZ’s acute disruptive effect on avoidance
responding (Li et al. 2010, 2012). In both studies, we found
that systemic pretreatment of DOI attenuated acute CLZ-
induced disruption of avoidance responding, possibly by ac-
tivating 5-HT2A receptor in the prefrontal cortex (McOmish
et al. 2012). Others also reported that systemic DOI at
10 mg/kg reversed the avoidance disruptive effect of
10 mg/kg CLZ (Browning et al. 2005), and its disruption of
maternal behavior (Zhao and Li 2009, 2010), suggesting the
reversal effect of DOI on CLZ is quite robust and is a gener-
alized effect. It is thus surprising that central infusion of DOI
into the mPFC had only a marginal reversal effect on the acute
effect of CLZ. It could mean that our selected doses of DOI or
the drug test conditions were not optimal. Since DOI does not
differentiate between 5-HT2A and 5-HT2C receptor subtypes,
and 5-HT2A and 5- HT2C receptors play opposing roles in
various brain functions and psychological processes (Di
Giovanni et al. 2000; Di Matteo et al. 2002; Winstanley
et al. 2004), including in the CAR (Grauer et al. 2009;
Wadenberg and Hicks 1999), it is conceivable that the chosen
doses of DOI might have activated both receptors, resulting in
a lowered reversal effect of DOI. Alternatively, it could mean
that 5-HT2A/2C receptor in other brain regions (e.g., lateral
septum, hippocampus, or ventral tegmental area) may play a
more important role in the regulation of CLZ’s acute effect
(Ichikawa et al. 2001b). Finally, because CLZ also has high
affinity for adrenergic α1 receptor, muscarinic M1 receptor
and histamine H1 receptor and moderate affinity for the D4
and 5-HT6 receptors, its actions on these receptors may also
contribute to its acute avoidance disruptive effect.
Another surprising finding is that microinjection of QUI in
the mPFC actually enhanced the acute effect of CLZ, an effect
opposite to that of DOI. Our previous systemic studies failed
to find such an effect in the CAR (Li et al. 2010) and in
maternal behavior (Zhao and Li 2009; 2010). The exact reason
for this discrepancy is not clear. One possibility is that QUI
might have different effects when it reaches different brain
areas. Because systemic QUI administration presumably im-
pacts a broader range of brain areas than central infusion,
some of its effects might have canceled each other out, yield-
ing no obvious net effect on CLZ when it is administrated
systemically. As to why QUI and DOI produced opposite
effects on the acute effect of CLZ, we speculate that activation
of D2/3 receptors in the mPFC byQUI may cause a decrease in
5-HT2A/2C receptor-mediated neurotransmission, which could
lead to a potentiation of the acute disruption of avoidance of
CLZ, as demonstrated in several studies involving other anti-
psychotic drugs (Wadenberg et al. 1998, 2001a). Furthermore,
both receptors are colocalized in the mPFC and they form
hetero-5-HT2A/D2 dimers and homo-5-HT2A/5-HT2A dimers
(Lukasiewicz et al. 2010), providing a physical basis for their
interactions. Therefore, the acute behavioral effect of CLZ is
likely mediated by its action on 5-HT2A/2C receptors
superimposed by its action on D2/3 receptors.
Consistent with our previous studies, repeated administra-
tion of CLZ caused a behavioral tolerance in the CAR test, an
effect opposite to behavioral sensitization typically associated
with many other antipsychotic drugs. As previously men-
tioned, we and others have repeatedly demonstrated CLZ
tolerance in the CAR test (Feng et al. 2013; Li et al. 2010,
2012; Qiao et al. 2013; Qin et al. 2013; Sanger 1985) and in
the PCP-induced hyperlocomotion test (Shu et al. 2014). CLZ
tolerance has also been reported in other behavioral domains.
For example, in a motor function and attention test, Stanford
and Fowler (1997) reported that CLZ-treated rats exhibited
tolerance to the drug’s suppressive effect on the amount of
time that rats were in contact with a force-sensing target disk.
In a fixed ratio 5 lever-pressing test, Trevitt et al. (1998) found
that acute CLZ treatment significantly suppressed lever press-
ing but this effect was attenuated with repeated drug admin-
istration. Similarly, Varvel et al. (2002) and Villanueva and
Porter (1993) also found that repeated dosing with CLZ pro-
duced tolerance to the rate-suppressing effects of CLZ in a
lever pressing task for food reward. CLZ-induced tolerance
has also been observed in a drug discrimination task (Goudie
et al. 2007a, b). Future studies could examine how the inter-
oceptive drug state contributes to CLZ tolerance and what
other behavioral mechanisms (e.g., associative learning and
contextual control) are involved.
The major contribution of the present study is its identifi-
cation of the neuroanatomical basis and receptor mechanisms
of CLZ tolerance. Previously, we showed that CLZ tolerance
development may be mediated by its D2/3 blockade-initiated
neural processes, as pretreatment of QUI during the 3-day
repeated avoidance test period enhanced the expression of
CLZ tolerance in the challenge test (Li et al. 2010). We are
currently examining the possible brain regions where QUI
may act to modulate CLZ tolerance. In light of the present
findings, we will focus on the mPFC as it is one likely target.
In the present study, we revealed that although intra-mPFC
infusion of DOI did not affect the acute avoidance disruptive
effect of CLZ as well as the tolerance development, it did
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dose-dependently suppress the expression of CLZ tolerance.
This finding highlights the importance of prefrontal 5-HT2A/
2C receptors in CLZ tolerance and is also consistent with a
recent finding showing that 5-HT2A receptors located on
forebrain glutamatergic neurons are critical for the motor-
suppressive effect of CLZ (McOmish et al. 2012). In that
study, McOmish et al. (2012) found that 5-HT2A KO mice
lack the locomotor-suppressing response to acute CLZ, sug-
gesting that the drug’s motor suppression effect (in wild-type
animals) is normally mediated by a blockade of 5-HT2A
receptors in the prefrontal cortex. This conclusion is strength-
ened by the observation that restoring 5-HT2A expression in
forebrain glutamatergic neurons was sufficient to restore the
locomotor-suppressing effect of CLZ. In light of these obser-
vations, we can conclude that CLZ’s acute suppression of
avoidance responding and intertrial crossing is mediated by
its antagonistic action on 5-HT2A receptor on forebrain gluta-
matergic neurons. Thus, by countering the antagonistic action
of CLZ on 5HT2A receptors, intra-mPFC infusions of DOI
might block the tolerance to CLZ. Because of the known
functional interaction between 5-HT2A receptor and D2 recep-
tor in the mPFC (Ichikawa et al. 2001b), these two receptor
mechanisms may diametrically regulate the development/
expression of CLZ tolerance. Ichikawa et al. (2001a, b)
showed that DOI treatment attenuates acute CLZ-induced
cortical dopamine release and combined blockade of 5-HT2A
and D2 receptors produces a greater increase in dopamine
release than that by each alone. It is thus conceivable that
DOI treatment in the mPFC would reduce D2-mediated neu-
rotransmission, possibly via the mPFC to ventral tegmental
area pathway (Vazquez-Borsetti et al. 2009) and/or NA path-
way, leading to a reduction in CLZ tolerance. This would
easily explain why QUI pretreatment potentiates CLZ toler-
ance (Li et al. 2010), as QUI stimulates D2/3 receptor and
increases associated dopamine neurotransmission. Based on
the available evidence, we would propose the following hy-
pothesis regarding the neuroreceptor mechanisms of CLZ
tolerance: CLZ tolerance is a form of neuroplasticity resulting
from CLZ’s dual action on 5-HT2A/2c and D2/3 receptors with
a yin–yang-like relation: the magnitude of CLZ tolerance can
be increased via stimulating D2/3 receptor (e.g., by QUI) and
decreased via stimulating 5-HT2A/2c receptor in the mPFC
(e.g., by DOI). This hypothesis is supported by the evidence
that repeated CLZ treatment causes an upregulation of D2
receptor level (Moran-Gates et al. 2006; Tarazi et al. 1998)
and a downregulation of 5-HT2A receptor in the mPFC
(Steward et al. 2004).
Finally, we want to comment on the finding that the abso-
lute magnitude of CLZ tolerance appears to be weaker in
Experiment 3 than in Experiment 2 (Fig. 4c, d versus
Fig. 5c, d). There are several procedural differences that may
contribute to this difference. In Experiment 2, rats were cen-
trally infused with SAL, DOI 5, or DOI 25 μg/0.5 μl/side into
the mPFC before each CLZ test, whereas in Experiment 3, no
such central infusion was done. In Experiment 2, rats were not
centrally injected with SAL or DOI before the challenge test,
whereas in Experiment 3, they were. In Experiment 2, DOI
was administered five times, whereas in Experiment 3, it was
only administered once. Also, Experiment 2 was run by a
female experimenter, and Experiment 3 was run by a male,
which could affect rats’ behavior differently, as shown by a
recent study (Sorge et al. 2014). All these differences could
potentially contribute to the magnitude difference between
these two experiments.
Taken together, we demonstrated that acute behavioral
effect of CLZ is likely mediated by its actions on the D2/3
and 5-HT2A/2C receptors (to a lesser extent) in the mPFC,
whereas its long-term tolerance effect might rely on the
neuroplasticity initiated by its antagonist action against 5-
HT2A/2C receptors in the mPFC. Because CLZ also has mul-
tiple actions on other receptors (e.g., 5-HT1A, D1, D3, H1, M1,
α1-noradrenergic, etc.), of which some have been implicated
in CLZ tolerance, future studies should expand this line of
research by systematically investigating the roles of these
receptors in the mediation of CLZ tolerance.
Acknowledgments We would like to thank Ms. Shinn-Yi Chou and
Ms. Natashia Swalve for their thoughtful comments on an earlier version
of this manuscript. Research reported in this paper was supported by the
National Institute of Mental Health of the National Institutes of Health
under award number R01MH085635 to Professor Ming Li.
Conflicts of interest The authors declare no conflict financial interests.
References
Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA Jr, Nestler
EJ (1999) Region-specific induction of deltaFosB by repeated ad-
ministration of typical versus atypical antipsychotic drugs. Synapse
33:118–128
Beyer CE, Steketee JD (2000) Intra-medial prefrontal cortex injection of
quinpirole, but not SKF 38393, blocks the acute motor-stimulant
response to cocaine in the rat. Psychopharmacology (Berl) 151:
211–218
Borison RL, Diamond BI (1983) Regional selectivity of neurolep-
tic drugs: an argument for site specificity. Brain Res Bull 11:
215–218
Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB
(2005) Clozapine and the mitogen-activated protein kinase signal
transduction pathway: implications for antipsychotic actions. Biol
Psychiatry 57:617–623
Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000)
Preferential modulation of mesolimbic vs. nigrostriatal dopaminer-
gic function by serotonin(2C/2B) receptor agonists: a combined
in vivo electrophysiological and microdialysis study. Synapse 35:
53–61
Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of
serotonin(2C) receptors in the control of brain dopaminergic func-
tion. Pharmacol Biochem Behav 71:727–734
1228 Psychopharmacology (2015) 232:1219–1230
Feng M, Sui N, Li M (2013) Environmental and behavioral controls of
the expression of clozapine tolerance: evidence from a novel across-
model transfer paradigm. Behav Brain Res 238:178–187
Gao J, Li Y, Zhu N, Brimijoin S, Sui N (2013) Roles of dopaminergic
innervation of nucleus accumbens shell and dorsolateral caudate-
putamen in cue-induced morphine seeking after prolonged absti-
nence and the underlying D1- and D2-like receptor mechanisms in
rats. J Psychopharmacol 27:181–191
Goudie AJ, Cole JC, Sumnall HR (2007a) Olanzapine and JL13 induce
cross-tolerance to the clozapine discriminative stimulus in rats.
Behav Pharmacol 18:9–17
Goudie AJ, Cooper GD, Cole JC, Sumnall HR (2007b) Cyproheptadine
resembles clozapine in vivo following both acute and chronic ad-
ministration in rats. J Psychopharmacol 21:179–190
Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C,
Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S (2009)
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency
of current antipsychotics. Psychopharmacology (Berl) 204:37–48
Ichikawa J, Dai J, Meltzer HY (2001a) DOI, a 5-HT2A/2C receptor
agonist, attenuates clozapine-induced cortical dopamine release.
Brain Res 907:151–155
Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer
HY (2001b) 5-HT(2A) and D(2) receptor blockade increases corti-
cal DA release via 5-HT(1A) receptor activation: a possible mech-
anism of atypical antipsychotic-induced cortical dopamine release. J
Neurochem 76:1521–1531
Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the
treatment-resistant schizophrenic. A double-blind comparison with
chlorpromazine. Arch Gen Psychiatry 45:789–796
Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003)
Antipsychotic dosing in preclinical models is often unrepresentative
of the clinical condition: a suggested solution based on in vivo
occupancy. J Pharmacol Exp Ther 305:625–631
Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs
on extracellular dopamine levels in rat medial prefrontal cortex and
nucleus accumbens. J Pharmacol Exp Ther 288:774–781
LiM, Fletcher PJ, Kapur S (2007) Time course of the antipsychotic effect and
the underlying behavioral mechanisms. Neuropsychopharmacology 32:
263–272
Li M, Sun T, Zhang C, Hu G (2010) Distinct neural mechanisms under-
lying acute and repeated administration of antipsychotic drugs in rat
avoidance conditioning. Psychopharmacology (Berl) 212:45–57
Li M, He W, Heupel K (2011) Administration of clozapine to a mother rat
potentiates pup ultrasonic vocalization in response to separation and re-
separation: contrast with haloperidol. Behav Brain Res 222:385–389
Li M, Sun T, Mead A (2012) Clozapine, but not olanzapine, disrupts
conditioned avoidance response in rats by antagonizing 5-HT2A/2C
receptors. J Neural Transm 119:497–505
Lukasiewicz S, Polit A, Kedracka-Krok S, Wedzony K, Mackowiak M,
Dziedzicka-WasylewskaM (2010) Hetero-dimerization of serotonin
5-HT(2A) and dopamine D(2) receptors. Biochim Biophys Acta
1803: 1347–58
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY,
Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE,
Severe J, Hsiao JK, Investigators C (2006) Effectiveness of cloza-
pine versus olanzapine, quetiapine, and risperidone in patients with
chronic schizophrenia who did not respond to prior atypical anti-
psychotic treatment. Am J Psychiatry 163:600–610
McOmish CE, Lira A, Hanks JB, Gingrich JA (2012) Clozapine-induced
locomotor suppression is mediated by 5-HT(2A) receptors in the
forebrain. Neuropsychopharmacology 37:2747–2755
Mead A, Li M (2009) Avoidance-suppressing effect of antipsychotic drugs
is progressively potentiated after repeated administration: an intero-
ceptive drug state mechanism. J Psychopharmacol 24:1045–1053
Meltzer H (2002) Mechanisms of action of atypical antipsychotic drugs. In:
Davis KL, Charney D, Coyle JT, Nemeroff C (eds)
Neuropsychopharmacology the fifth generation of progress: an official
publication of the American College of Neuropsychopharmacology.
Lippincott Williams & Wilkins, Philadelphia
Moran-Gates T, Gan L, Park YS, Zhang K, Baldessarini RJ, Tarazi FI
(2006) Repeated antipsychotic drug exposure in developing rats:
dopamine receptor effects. Synapse 59:92–100
Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Suzuki H, Kuroda S (2000)
Clozapine- and olanzapine-induced Fos expression in the rat medial
prefrontal cortex is mediated by beta-adrenoceptors.
Neuropsychopharmacology 23:162–169
Paxinos G, Watson C (2004) The rat brain in stereotaxic coordinates, 5th
edn. Elsevier/Academic, Amsterdam
Pehek EA, Yamamoto BK (1994) Differential effects of locally adminis-
tered clozapine and haloperidol on dopamine efflux in the rat pre-
frontal cortex and caudate-putamen. J Neurochem 63:2118–2124
Qiao J, Li H, Li M (2013) Olanzapine sensitization and clozapine toler-
ance: from adolescence to adulthood in the conditioned avoidance
response model. Neuropsychopharmacology 38:513–524
Qin R, Chen Y, Li M (2013) Repeated asenapine treatment produces a
sensitization effect in two preclinical tests of antipsychotic activity.
Neuropharmacology 75C:356–364
Reynolds SM, Berridge KC (2001) Fear and feeding in the nucleus
accumbens shell: rostrocaudal segregation of GABA-elicited defen-
sive behavior versus eating behavior. J Neurosci 21:3261–3270
Richard JM, Berridge KC (2011)Metabotropic glutamate receptor block-
ade in nucleus accumbens shell shifts affective valence towards fear
and disgust. Eur J Neurosci 33:736–747
Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of
Fos-like immunoreactivity in the forebrain as predictors of atypical
antipsychotic activity. J Pharmacol Exp Ther 271:1058–1066
Sanger DJ (1985) The effects of clozapine on shuttle-box avoidance
responding in rats: comparisons with haloperidol and chlordiaz-
epoxide. Pharmacol Biochem Behav 23:231–236
Shu Q, Hu G, Li M (2014) Adult response to olanzapine or clozapine
treatment is altered by adolescent antipsychotic exposure: a preclin-
ical test in the phencyclidine hyperlocomotion model. J
Psychopharmacol 28:363–375
Sipes TE, GeyerMA (1997) DOI disrupts prepulse inhibition of startle in rats
via 5-HT2A receptors in the ventral pallidum. Brain Res 761:97–104
Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH,
Wieskopf JS, Acland EL, Dokova A, Kadoura B, Leger P,
Mapplebeck JC, McPhail M, Delaney A, Wigerblad G, Schumann
AP, Quinn T, Frasnelli J, Svensson CI, Sternberg WF, Mogil JS
(2014) Olfactory exposure to males, including men, causes stress
and related analgesia in rodents. Nat Meth
Sotoyama H, Zheng Y, Iwakura Y, Mizuno M, Aizawa M, Shcherbakova
K, Wang R, Namba H, Nawa H (2011) Pallidal hyperdopaminergic
innervation underlying D2 receptor-dependent behavioral deficits in
the schizophrenia animal model established by EGF. PLoS One 6:
e25831
Stanford JA, Fowler SC (1997) Subchronic effects of clozapine and
haloperidol on rats’ forelimb force and duration during a press-
while-licking task. Psychopharmacology (Berl) 130:249–253
Steward LJ, Kennedy MD, Morris BJ, Pratt JA (2004) The atypical
antipsychotic drug clozapine enhances chronic PCP-induced regu-
lation of prefrontal cortex 5-HT2A receptors. Neuropharmacology
47:527–537
Sun T, Hu G, Li M (2009) Repeated antipsychotic treatment progressive-
ly poten t ia tes inh ib i t ion on phencycl id ine- induced
hyperlocomotion, but attenuates inhibition on amphetamine-
induced hyperlocomotion: relevance to animal models of antipsy-
chotic drugs. Eur J Pharmacol 602:334–342
Tarazi FI, Yeghiayan SK, Neumeyer JL, Baldessarini RJ (1998) Medial
prefrontal cortical D2 and striatolimbic D4 dopamine receptors:
common targets for typical and atypical antipsychotic drugs. Prog
Neuropsychopharmacol Biol Psychiatry 22:693–707
Psychopharmacology (2015) 232:1219–1230 1229
Trevitt J, Atherton A, Aberman J, Salamone JD (1998) Effects of sub-
chronic administration of clozapine, thioridazine and haloperidol on
tests related to extrapyramidal motor function in the rat.
Psychopharmacology (Berl) 137:61–66
Varvel SA, Vann RE, Wise LE, Philibin SD, Porter JH (2002) Effects of
antipsychotic drugs on operant responding after acute and repeated
administration. Psychopharmacology (Berl) 160:182–191
Vazquez-Borsetti P, Cortes R, Artigas F (2009) Pyramidal neurons in rat
prefrontal cortex projecting to ventral tegmental area and dorsal
raphe nucleus express 5-HT2A receptors. Cereb Cortex 19:1678–
1686
Villanueva HF, Porter JH (1993) Differential tolerance to the behavioral
effects of chronic pimozide and clozapine on multiple random
interval responding in rats. Behav Pharmacol 4:201–208
Wadenberg ML, Hicks PB (1999) The conditioned avoidance response
test re-evaluated: is it a sensitive test for the detection of potentially
atypical antipsychotics? Neurosci Biobehav Rev 23:851–862
Wadenberg ML, Hicks PB, Richter JT, Young KA (1998) Enhancement
of antipsychoticlike properties of raclopride in rats using the selec-
tive serotonin2A receptor antagonist MDL 100,907. Biol Psychiatry
44:508–515
Wadenberg MG, Browning JL, Young KA, Hicks PB (2001a)
Antagonism at 5-HT(2A) receptors potentiates the effect of haloper-
idol in a conditioned avoidance response task in rats. Pharmacol
Biochem Behav 68:363–370
Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001b)
Dopamine D(2) receptor occupancy is a common mechanism un-
derlying animal models of antipsychotics and their clinical effects.
Neuropsychopharmacology 25:633–641
Wan FJ, Swerdlow NR (1993) Intra-accumbens infusion of quinpirole
impairs sensorimotor gating of acoustic startle in rats.
Psychopharmacology (Berl) 113:103–109
Winstanley CA, Theobald DE, Dalley JW, Glennon JC, Robbins TW
(2004) 5-HT2A and 5-HT2C receptor antagonists have opposing
effects on a measure of impulsivity: interactions with global 5-HT
depletion. Psychopharmacology (Berl) 176:376–385
Wischhof L, Hollensteiner KJ, Koch M (2011) Impulsive behaviour in
rats induced by intracortical DOI infusions is antagonized by co-
administration of an mGlu2/3 receptor agonist. Behav Pharmacol
22:805–813
Young CD, Bubser M, Meltzer HY, Deutch AY (1999) Clozapine pre-
treatment modifies haloperidol-elicited forebrain Fos induction: a
regionally-specific double dissociation. Psychopharmacology (Berl)
144:255–263
Zhang C, LiM (2012) Contextual and behavioral control of antipsychotic
sensitization induced by haloperidol and olanzapine. Behav
Pharmacol 23:66–79
Zhao C, Li M (2009) The receptor mechanisms underlying the disruptive
effects of haloperidol and clozapine on rat maternal behavior: a
double dissociation between dopamine D(2) and 5-HT(2A/2C) re-
ceptors. Pharmacol Biochem Behav
Zhao C, Li M (2010) C-Fos identification of neuroanatomical sites
associated with haloperidol and clozapine disruption of maternal
behavior in the rat. Neuroscience 166:1043–1055
Zhao C, Sun T, Li M (2012) Neural basis of the potentiated inhibition of
repeated haloperidol and clozapine treatment on the phencyclidine-
induced hyperlocomotion. Prog Neuropsychopharmacol Biol
Psychiatry 38:175–182
1230 Psychopharmacology (2015) 232:1219–1230
